Eli Lilly tops revenue estimates on diabetes drug boost [Reuters]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Reuters
Eli Lilly tops revenue estimates on diabetes drug boost - Reuters 1 Min Read (Reuters) - Eli Lilly and Co ( LLY.N ) edged past Wall Street estimates for quarterly revenue on Tuesday, as higher sales of its top-selling diabetes drug, Trulicity, helped offset the impact of generic competition on its erectile dysfunction drug, Cialis. The drugmaker posted net income of $1.33 billion, or $1.44 per share, in the quarter ended June 30, compared with a loss of $259.9 million, or 25 cents per share, a year earlier. It had recorded an acquisition-related charge of $1.62 billion in the prior year quarter. Revenue rose to $5.64 billion from $5.59 billion, above Wall Street estimates of $5.59 billion. Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Anil D'Silva All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2019 Reuters. All Rights Reserved. Eli Lilly tops revenue estimates on diabetes drug boost (Reuters) - Eli Lilly and C
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- This Company Is Doubling Down on AI. Is the Stock a Buy? [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid' launch [CNBC]CNBC
- Eli Lilly: Exceptional 2025, But Rising Headwinds Loom In 2026 [Seeking Alpha]Seeking Alpha
- Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead [Yahoo! Finance]Yahoo! Finance
- JPM26: Eli Lilly's obesity drugs target commercial and governmental access [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 1/8/26 - Form 4
- 1/6/26 - Form 3
- 1/6/26 - Form 4
- LLY's page on the SEC website